Agenus Inc. - Common Stock (AGEN)

Agenus (NASDAQ:AGEN) told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while working to strengthen its financial position and pursue regulatory pathways in the United States and Euro

Agenus (AGEN) Q2 2025 Earnings Call Transcript

Agenus (AGEN) Q3 2024 Earnings Call Transcript

Agenus (AGEN) Q1 2025 Earnings Call Transcript

Agenus (AGEN) Q4 2024 Earnings Call Transcript

Agenus reports mixed Q3 2025 results with a revenue miss but strong clinical progress for its cancer drug BOT/BAL, including a new Phase 3 trial.

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.